Related references
Note: Only part of the references are listed.NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
K. Byrgazov et al.
LEUKEMIA (2017)
Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach
Xiaochu Ma et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
David Grimwade et al.
BLOOD (2016)
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
Weiguo Zhang et al.
CANCER RESEARCH (2016)
The kinome 'at large' in cancer
Emmy D. G. Fleuren et al.
NATURE REVIEWS CANCER (2016)
Ten things you should know about protein kinases: IUPHAR Review 14
Doriano Fabbro et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Ponatinib: Accelerated Disapproval
Justin F. Gainor et al.
ONCOLOGIST (2015)
A Multi-parameter In Vitro Screen in Human Stem Cell-Derived Cardiomyocytes Identifies Ponatinib-Induced Structural and Functional Cardiac Toxicity
Dominique R. Talbert et al.
TOXICOLOGICAL SCIENCES (2015)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
Cedric Dos Santos et al.
BLOOD (2013)
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Catherine C. Smith et al.
BLOOD (2013)
Activity-based kinase profiling of approved tyrosine kinase inhibitors
Daisuke Kitagawa et al.
GENES TO CELLS (2013)
Acute myeloid leukemia associated with FGFR1 abnormalities
Hyeyoung Lee et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)-ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors
Mingshan Gao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo
Yoriko Saito et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases
Kenneth Verstraete et al.
NATURE REVIEWS CANCER (2012)
FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia The Start of an Era?
Naveen Pemmaraju et al.
CANCER (2011)
Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Survey of Activated FLT3 Signaling in Leukemia
Ting-lei Gu et al.
PLOS ONE (2011)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
MSK1 activation in acute myeloid leukemia cells with FLT3 mutations
T. Odgerel et al.
LEUKEMIA (2010)
Targeting the ANGPT-TIE2 pathway in malignancy
Hanhua Huang et al.
NATURE REVIEWS CANCER (2010)
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Jianbiao Zhou et al.
BLOOD (2009)
Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells
Tiziana Grafone et al.
HEMATOLOGICAL ONCOLOGY (2008)
Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
Yukiyasu Ozawa et al.
LEUKEMIA RESEARCH (2008)
A critical role for Lyn in acute myeloid leukemia
Ceric Dos Santos et al.
BLOOD (2008)
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Chunaram Choudhary et al.
BLOOD (2007)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability
JR Riggs et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
HS Radomska et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
